scholarly journals Circulating microRNA profile as a potential biomarker for obstructive sleep apnea diagnosis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Fernando Santamaria-Martos ◽  
Iván Benítez ◽  
Francisco Ortega ◽  
Andrea Zapater ◽  
Cristina Giron ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Differentially Expressed ◽  
Mirna Profile ◽  
Circulating Microrna ◽  
Circulating Mirna ◽  
Cpap Treatment ◽  
Potential Biomarker ◽  
Obstructive Sleep ◽  
Differentially Expressed Mirnas

Abstract Evaluation of microRNAs (miRNAs) could allow characterization of the obstructive sleep apnea (OSA) and help diagnose it more accurately. We aimed to examine circulating miRNA profiles to establish the differences between non-OSA and OSA patients. Additionally, we aimed to analyse the effect of continuous positive airway pressure (CPAP) treatment on the miRNA profile. This observational, longitudinal study included 230 subjects referred to the Sleep Unit due to suspected OSA. Expression profiling of 188 miRNAs in plasma was performed in 27 subjects by TaqMan-Low-Density-Array. OSA-related miRNAs were selected for validation by RT-qPCR in 203 patients. Prediction models were built to discriminate between non-OSA and OSA: 1) NoSAS-score, 2) differentially expressed miRNAs, and 3) combination of NoSAS-score plus miRNAs. The differentially expressed miRNAs were measured after 6 months of follow-up. From the 14 miRNAs selected for validation, 6 were confirmed to be differentially expressed. The areas under the curve were 0.73 for the NoSAS-score, 0.81 for the miRNAs and 0.86 for the combination. After 6 months of CPAP treatment, miRNA levels in the OSA group seem to approximate to non-OSA levels. A cluster of miRNAs was identified to differentiate between non-OSA and OSA patients. CPAP treatment was associated with changes in the circulating miRNA profile.

scholarly journals Expression Profile Analysis and Image Observation of miRNA in Serum of Patients with Obstructive Sleep Apnea-Hypopnea Syndrome

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Haiyan Shao ◽  
Peihong Shen ◽  
Junfeng Chen
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Expression Profile ◽  
Theoretical Basis ◽  
Target Genes ◽  
Profile Analysis ◽  
Differentially Expressed ◽  
Obstructive Sleep ◽  
Differentially Expressed Mirnas ◽  
Hypopnea Syndrome

The expression profile and image observation of miRNA in serum of patients with obstructive sleep apnea-hypopnea syndrome were investigated. Bioinformatics methods were used to explore the molecular mechanism of obstructive sleep apnea-hypopnea syndrome (OSAHS)-related hypertension and explore the differentially expressed core miRNAs and regulatory factors, providing a theoretical basis for seeking molecular targets for clinical diagnosis and treatment. The miRNA datasets of patients with OSAHS and those with hypertension were downloaded from the public database to obtain differentially expressed miRNAs and explore the biological processes and pathways involved in the target genes. The core miRNAs and competitive endogenous RNA (ceRNA) transcription factors (TFs) were obtained by database mining and Cytoscape network analysis. The results showed that 2,579 differentially expressed miRNAs were obtained from the GSE112093 dataset. Seven upregulated miRNAs (hsa-miR-7107-5p, hsa-miR-7110-5p, hsa-miR-595, hsa-miR-1268b, hsa-miR-3064-5p, hsa-miR-68565p, and hsa-miR-1180-3p) and one downregulated miRNA (hsa-miR-22-3p) were obtained from the GSE112093 dataset. It is proved that hsa-miR-22-3p, hsa-miR-595, hsa-miR-6856-5pKcnq1ot1, neat1, Tsix, ERG, kdm2b, and Runx1 may be involved in the pathogenesis of OSAHS-related hypertension, which provided a theoretical basis for the mechanism research and clinical treatment of OSAHS.

Neuropsychological functioning after CPAP treatment in obstructive sleep apnea: A meta-analysis

2013 ◽  
Vol 17 (5) ◽  
pp. 341-347 ◽  
Author(s):  
Wytske A. Kylstra ◽  
Justine A. Aaronson ◽  
Winni F. Hofman ◽  
Ben A. Schmand
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Neuropsychological Functioning ◽  
Meta Analysis ◽  
Cpap Treatment ◽  
Obstructive Sleep

scholarly journals Endothelial Function in Normotensive Men with Obstructive Sleep Apnea Before and 6 Months After CPAP Treatment

SLEEP ◽  
2009 ◽  
Vol 32 (10) ◽  
pp. 1257-1263 ◽  
Author(s):  
Nihal Akar Bayram ◽  
Bülent Ciftci ◽  
Telat Keles ◽  
Tahir Durmaz ◽  
Sibel Turhan ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Endothelial Function ◽  
Cpap Treatment ◽  
Obstructive Sleep

scholarly journals 0817 ADHERENCE TO CPAP TREATMENT IN WOMEN WITH OBSTRUCTIVE SLEEP APNEA

SLEEP ◽  
2017 ◽  
Vol 40 (suppl_1) ◽  
pp. A302-A302
Author(s):  
E Libman ◽  
S Bailes ◽  
C Fichten ◽  
D Rizzo ◽  
L Creti ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Cpap Treatment ◽  
Obstructive Sleep

scholarly journals CPAP treatment, glycemia and diabetes risk in obstructive sleep apnea and comorbid cardiovascular disease

2020 ◽  
Author(s):  
Kelly A. Loffler ◽  
Emma Heeley ◽  
Ruth Freed ◽  
Rosie Meng ◽  
Lia R. Bittencourt ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Glycemic Control ◽  
Usual Care ◽  
Serum Glucose ◽  
Cpap Therapy ◽  
Cpap Treatment ◽  
Obstructive Sleep

Objective: Despite evidence of a relationship between obstructive sleep apnea (OSA), metabolic dysregulation and diabetes mellitus (DM), it is uncertain whether OSA treatment can improve metabolic parameters. We sought to determine effects of long-term continuous positive airway pressure (CPAP) treatment on glycemic control and DM risk in patients with cardiovascular disease (CVD) and OSA. <strong>Research Design and Methods: </strong>Blood, medical history, and personal data were collected in a <strong>substudy of 888 participants in the </strong>Sleep Apnea Cardiovascular Endpoints (SAVE) trial in which patients with OSA and stable CVD were r<strong>andomized</strong> to receive CPAP plus Usual Care, or Usual Care alone. Serum glucose and glycated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) were measured at baseline, and six months, two- and four years, and incident diabetes diagnoses recorded. Results: Median follow-up was 4.3 years. In those with pre-existing DM (n=274), there was no significant difference between CPAP and Usual Care groups in serum glucose, HbA<sub>1c</sub> or anti-diabetic medications during follow-up. There were also no significant between-group differences in participants with pre-diabetes (n=452), nor in new diagnoses of DM. Interaction testing suggested that women with diabetes did poorly in the Usual Care group while their counterparts on CPAP therapy remained stable. <strong>Conclusions</strong><b>:</b> Among patients with established CVD and OSA, we found no evidence that CPAP therapy over several years affected glycemic control in those with diabetes or pre-diabetes, or DM risk over standard of care treatment. The potential differential effect according to sex deserves further investigation.

Sign in / Sign up

Export Citation Format

Share Document